Even standard dose levels (ifosfamide 6 g m−2 and doxorubicin 60 mg m−2 and G-CSF) led to severe neutropenia in 49%, anaemia in 23%, and thrombopenia in 15% of patients (Worden et al, 2005). This evidence concerns the gene CSF3 and neutropenia.